Promedior, Inc.
Industry
- Pharmaceuticals
Latest on Promedior, Inc.
Galecto Inc. has become the latest company to fail at developing a new therapy for idiopathic pulmonary fibrosis (IPF) and has decided to concentrate its research efforts on severe liver diseases. Th
Boehringer Ingelheim GmbH markets one of the two drugs approved for idiopathic pulmonary fibrosis (IPF) in Ofev but has high hopes that its new treatment could actually stop the lung-scarring disease
Nearly 800 new drugs and vaccines in development for COVID-19 helped push the total size of the biopharma R&D pipeline to 18,582 products at the start of 2021, new analysis by Citeline’s drug database
The venture capital spending spree in 2020 has led to many notably large biopharmaceutical company funding rounds, making $100m-plus mega-rounds less surprising than they used to be. The latest entran